Mosaic RNA Phage VLPs Carrying Domain III of the West Nile Virus E Protein
Overview
Molecular Biology
Authors
Affiliations
The virus-neutralising domain III (DIII) of the West Nile virus glycoprotein E was exposed on the surface of RNA phage AP205 virus-like particles (VLPs) in mosaic form. For this purpose, a 111 amino acid sequence of DIII was added via amber or opal termination codons to the C-terminus of the AP205 coat protein, and mosaic AP205-DIII VLPs were generated by cultivation in amber- or opal-suppressing Escherichia coli strains. After extensive purification to 95 % homogeneity, mosaic AP205-DIII VLPs retained up to 11-16 % monomers carrying DIII domains. The DIII domains appeared on the VLP surface because they were fully accessible to anti-DIII antibodies. Immunisation of BALB/c mice with AP205-DIII VLPs resulted in the induction of specific anti-DIII antibodies, of which the level was comparable to that of the anti-AP205 antibodies generated against the VLP carrier. The AP205-DIII-induced anti-DIII response was represented by a significant fraction of IgG2 isotype antibodies, in contrast to parallel immunisation with the DIII oligopeptide, which failed to induce IgG2 isotype antibodies. Formulation of AP-205-DIII VLPs in alum adjuvant stimulated the level of the anti-DIII response, but did not alter the fraction of IgG2 isotype antibodies. Mosaic AP205-DIII VLPs could be regarded as a promising prototype of a putative West Nile vaccine.
Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design.
Vernhes E, Cherif L, Ducrot N, Vanbergue C, Ouldali M, Zig L NPJ Vaccines. 2024; 9(1):6.
PMID: 38177231 PMC: 10766600. DOI: 10.1038/s41541-023-00798-5.
Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.
Tumban E Methods Mol Biol. 2023; 2738:411-423.
PMID: 37966612 DOI: 10.1007/978-1-0716-3549-0_24.
Stander J, Chabeda A, Rybicki E, Meyers A Front Plant Sci. 2021; 12:738619.
PMID: 34589108 PMC: 8475786. DOI: 10.3389/fpls.2021.738619.
RNA Phage VLP-Based Vaccine Platforms.
Peabody D, Peabody J, Bradfute S, Chackerian B Pharmaceuticals (Basel). 2021; 14(8).
PMID: 34451861 PMC: 8401894. DOI: 10.3390/ph14080764.
Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines.
Zhang N, Li C, Jiang S, Du L Vaccines (Basel). 2020; 8(3).
PMID: 32867194 PMC: 7565697. DOI: 10.3390/vaccines8030481.